Logo image of HSDT

HELIUS MEDICAL TECHNOLOGIE-A (HSDT) Stock Fundamental Analysis

NASDAQ:HSDT - Nasdaq - US42328V8019 - Common Stock - Currency: USD

3.51  -0.08 (-2.23%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HSDT. HSDT was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While HSDT seems to be doing ok healthwise, there are quite some concerns on its profitability. HSDT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HSDT had negative earnings in the past year.
In the past year HSDT has reported a negative cash flow from operations.
HSDT had negative earnings in each of the past 5 years.
In the past 5 years HSDT always reported negative operating cash flow.
HSDT Yearly Net Income VS EBIT VS OCF VS FCFHSDT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

HSDT's Return On Assets of -374.97% is on the low side compared to the rest of the industry. HSDT is outperformed by 98.40% of its industry peers.
With a Return On Equity value of -1020.63%, HSDT is not doing good in the industry: 88.30% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -374.97%
ROE -1020.62%
ROIC N/A
ROA(3y)-175.99%
ROA(5y)-174.45%
ROE(3y)-552.67%
ROE(5y)-436.83%
ROIC(3y)N/A
ROIC(5y)N/A
HSDT Yearly ROA, ROE, ROICHSDT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20K -20K

1.3 Margins

HSDT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HSDT Yearly Profit, Operating, Gross MarginsHSDT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

More info and screens

5

2. Health

2.1 Basic Checks

HSDT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HSDT has more shares outstanding
HSDT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for HSDT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HSDT Yearly Shares OutstandingHSDT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K
HSDT Yearly Total Debt VS Total AssetsHSDT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

Based on the Altman-Z score of -83.11, we must say that HSDT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of HSDT (-83.11) is worse than 96.28% of its industry peers.
HSDT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -83.11
ROIC/WACCN/A
WACC9.11%
HSDT Yearly LT Debt VS Equity VS FCFHSDT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.69 indicates that HSDT should not have too much problems paying its short term obligations.
HSDT's Current ratio of 1.69 is on the low side compared to the rest of the industry. HSDT is outperformed by 72.87% of its industry peers.
A Quick Ratio of 1.12 indicates that HSDT should not have too much problems paying its short term obligations.
The Quick ratio of HSDT (1.12) is worse than 73.40% of its industry peers.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.12
HSDT Yearly Current Assets VS Current LiabilitesHSDT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

HSDT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.77%, which is quite impressive.
HSDT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -19.25%.
Measured over the past years, HSDT shows a very negative growth in Revenue. The Revenue has been decreasing by -19.09% on average per year.
EPS 1Y (TTM)75.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.44%
Revenue 1Y (TTM)-19.25%
Revenue growth 3Y0%
Revenue growth 5Y-19.09%
Sales Q2Q%-63.7%

3.2 Future

HSDT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.20% yearly.
The Revenue is expected to grow by 177.16% on average over the next years. This is a very strong growth
EPS Next Y88.61%
EPS Next 2Y39.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.97%
Revenue Next 2Y38.13%
Revenue Next 3Y346.25%
Revenue Next 5Y177.16%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HSDT Yearly Revenue VS EstimatesHSDT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M
HSDT Yearly EPS VS EstimatesHSDT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10K -20K -30K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HSDT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSDT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSDT Price Earnings VS Forward Price EarningsHSDT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSDT Per share dataHSDT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

HSDT's earnings are expected to grow with 39.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.2%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSDT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HELIUS MEDICAL TECHNOLOGIE-A

NASDAQ:HSDT (5/29/2025, 4:56:58 PM)

3.51

-0.08 (-2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners6.5%
Inst Owner Change14.67%
Ins Owners0.2%
Ins Owner Change0%
Market Cap1.86M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.71%
Min EPS beat(2)-6.38%
Max EPS beat(2)13.79%
EPS beat(4)2
Avg EPS beat(4)-2.41%
Min EPS beat(4)-25.49%
Max EPS beat(4)13.79%
EPS beat(8)6
Avg EPS beat(8)16.75%
EPS beat(12)9
Avg EPS beat(12)18.89%
EPS beat(16)11
Avg EPS beat(16)13.63%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-51.96%
Max Revenue beat(2)49.02%
Revenue beat(4)2
Avg Revenue beat(4)-12.66%
Min Revenue beat(4)-66.67%
Max Revenue beat(4)49.02%
Revenue beat(8)4
Avg Revenue beat(8)-15.25%
Revenue beat(12)6
Avg Revenue beat(12)-18.93%
Revenue beat(16)9
Avg Revenue beat(16)-3.49%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1400%
EPS NQ rev (3m)-381.13%
EPS NY rev (1m)-1400%
EPS NY rev (3m)-284%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.29
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-47.4
EYN/A
EPS(NY)-5.35
Fwd EYN/A
FCF(TTM)-21.84
FCFYN/A
OCF(TTM)-21.84
OCFYN/A
SpS0.82
BVpS2.42
TBVpS2.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -374.97%
ROE -1020.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-175.99%
ROA(5y)-174.45%
ROE(3y)-552.67%
ROE(5y)-436.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.12
Altman-Z -83.11
F-Score3
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)13.37%
Cap/Sales(3y)2.54%
Cap/Sales(5y)5.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.44%
EPS Next Y88.61%
EPS Next 2Y39.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-19.25%
Revenue growth 3Y0%
Revenue growth 5Y-19.09%
Sales Q2Q%-63.7%
Revenue Next Year8.97%
Revenue Next 2Y38.13%
Revenue Next 3Y346.25%
Revenue Next 5Y177.16%
EBIT growth 1Y-12.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6%
OCF growth 3YN/A
OCF growth 5YN/A